Review

DNA Methylation Modulates Aging Process in Adipocytes

Hao Xie¹, #, Xin Liu², #, Qing Zhou¹, Teng Huang¹, Lu Zhang¹, Jia Gao¹, Yuhan Wang¹, Yanjun Liu¹, ³, Tong Yan³, Shu Zhang¹, *, Cong-Yi Wang¹, *

¹The Center for Biomedical Research, Department of Respiratory and Critical Care Medicine, NHC Key Laboratory of Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ²Department of Interventional Radiology, Renmin Hospital of Wuhan University, Wuhan, China. ³The Center for Obesity and Metabolic Health, Affiliated Hospital of Southwest Jiaotong University, The Third People’s Hospital of Chengdu, Sichuan, China. ⁴The Center of Gastrointestinal and Minimally Invasive Surgery, Department of General Surgery, The Third People’s Hospital of Chengdu & The affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan, China.

[Received May 22, 2021; Revised September 3, 2021; Accepted September 4, 2021]

ABSTRACT: Aging has been recognized to be a highly complex biological health problem with a high risk of chronic diseases, including type 2 diabetes, atherosclerosis, chronic bronchitis or emphysema, cancer and Alzheimer’s disease. Particularly, age-related turnover in adipose tissue is a major contributor to metabolic syndromes and shortened lifespan. Adipocytes undergo senescence in early stage, which results in adipose tissue metabolic dysfunction, redistribution, and inflammation. The well-established association between DNA methylation (DNAm) and aging has been observed in the past few decades. Indeed, age-related alteration in DNAm is highly tissue-specific. This review intends to summarize the advancements how DNAm changes coupled with aging process in adipose tissue, by which DNAm regulates cellular senescence, metabolic function, adipokine secretion and beiging process in adipocytes. Elucidation of the effect of DNAm on adipose aging would have great potential to the development of epigenetic therapeutic strategies against aging-related diseases in clinical settings.

Key words: DNA methylation, aging, adipocytes, adipose tissue

Adipose tissue (AT) was originally regarded as the largest energy storage organ in the body, but it has been subsequently recognized to be an endocrine organ capable of synthesizing a number of biologically active compounds that regulate metabolic homeostasis. Composed of mature adipocytes, luxuriant microvasculature and complicated stromal vascular fraction (SVF), the heterogeneous adipose tissue is roughly divided into two predominant types in mammals: white adipose tissue (WAT) and classical brown adipose tissue (BAT) [1]. Mature adipocytes derived from adipose progenitor cells are the main functional undertakers in adipose tissue. The SVF is composed of many different cell types, including adipose progenitor cells, endothelial cells, fibroblasts and immune cells. In response to energy demands, WAT including subcutaneous, visceral, omental and local-specific subtypes, plays a significant role in maintaining systemic energy homeostasis through the interplay between lipogenesis and lipolysis [2]. In the case of an urgent demand for energy, lipid mobilization is activated to breakdown stored triglycerides into fatty acids and glycerol [3]. Moreover, white adipocytes are capable of handling cytotoxic free fatty acids (FFAs) by converting them into less damaging neutral triglycerides, thereby protecting other tissues from lipotoxicity [4]. Once the capacity of lipid storage in AT is impaired (e.g.,...
overnutrition or aging), lipids cannot be absorbed by the subcutaneous AT, which leads to ectopic lipid deposition [5, 6]. Age-related lipid deposition in the liver is associated with the development of fatty liver disease, while in the muscle it is correlated with insulin resistance and glucose intolerance [7, 8]. Additionally, BAT utilizes fatty acids and glucose for thermogenesis manifested by the overexpression of uncoupling protein-1 (UCP1) to generate heat [9, 10]. The unique non-shivering thermogenic property of brown adipocytes is activated and regulated through the functional properties of BAT has also been found to secrete fibroblast growth factor 21 (FGF21), myostatin and C-X-C motif chemokine ligand-14 (CXCL14), thereby enhancing heat generation and regulating the functional properties of skeletal muscle and macrophages [32-34]. Ependymin-related protein 1 (EPDR1), a novel batokine secreted from human brown adipocytes, improves whole-body metabolism [35]. Therefore, AT is also an endocrine organ in addition to being energy reservoir. Unfortunately, aging occurs in AT even under 30 years old in humans as manifested by the redistribution of fat in the body [36, 37]. There is compelling evidence that its functionality is significantly impacted by the aging process, which tightly controlled by multiple mechanisms, particularly by the epigenetic alterations such as the changes of DNA methylation (DNAm).

Indeed, DNAm has now been recognized as one of the major characteristic epigenetic alterations in mammalian cellular senescence [38, 39], which manifests a significant influence on the development and differentiation of stem cells or progenitor cells [40, 41]. DNAm is processed by five methyltransferases, DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L [42-45]. DNA methylome-encoded information is read by a family of methyl-CpG–binding domain (MBD) proteins, including MBD1, MBD2, MBD3, MBD4 and MeCP2 [43, 46-48]. In contrast, DNA demethylation is processed by two different pathways: one is the ten-eleven translocation enzymes (TETs) that oxidize the methylated base, and the other is activation induced deaminase (AID), which deaminates the methylated or a nearby base by two different pathways: one is the ten-eleven translocation enzymes (TETs) that oxidize the methylated base, and the other is activation induced deaminase (AID), which deaminates the methylated or a nearby base [49] (Table 1). In general, DNAm occurs at CpG sites, but a few do occur in non-CpG sites, which directly changes the accessibility of DNA to transcription factors and other DNA binding proteins [50]. Hypomethylation CpGs in the regulatory regions are generally correlated with constitutive upregulation of gene expression, while hypermethylated CpGs contribute to transcriptional repression [51]. In response to genetic inheritance and environmental insult, the dynamics of cellular methylation and demethylation jointly regulate gene expression and cell function relevant to aging process. Therefore, in this review we sought to update the advancement of DNAm, a major epigenetic mechanism, in the regulation of aging process in adipose tissues.

Table 1. Changes in DNA methyltransferases activity during aging.

| Methyltransferases | Function | Activity | Reference |
|--------------------|----------|----------|-----------|
| DNMT1              | Maintenance methyltransferase | Decreased in fibroblasts, oligodendrocyte progenitor cells | [44,45] |
| DNMT2              | Methylation of cytosine 38 in the anticodon loop of aspartic acid transfer RNA | Not clear | |
| DNMT3a/3b          | De novo methylation | Increased in fibroblasts, oligodendrocyte progenitor cells | [44,45] |
| DNMT3L             | Does not contain methyltransferase active site motifs but binds to the carboxyl-terminal domains of DNMT3a/3b | Not clear | |

The relationship between DNA demethylases (TETs and AID) activity and aging is not clear. DNMT: DNA methyltransferase; TETs: ten-eleven translocation enzymes; AID: activation induced deaminase.
Senescence induces redistribution and cellular dysfunction of adipose tissues

Cellular and molecular features of aging are associated with cellular senescence, dysregulation of nutritional sensing, and stem cell exhaustion [52]. Cellular senescence is also a defensive mechanism involved in embryogenesis and tumorigenic cell neutralization. Once senescent cell abundance exceeds a critical threshold, systemic dysfunction occurs. The lifelong aging process is initiated in all tissues over time, and particularly occurs far earlier in AT, as evidenced by the presence of facial wrinkles along with fat redistribution (e.g., skin fold, cheek sag, thin hands and legs) [53, 54]. A characteristic feature of fat redistribution during the aging process is the remarkable reduction in the subcutaneous AT and BAT along with an increase in visceral AT [55, 56]. For example, the presence of scapular BAT during infancy is gradually lost with age [57], and adolescent active BAT can only be detected in the supraclavicular region after cold exposure and becomes undetectable in individuals over the age of sixty [58-60].

In general, the mean white adipocyte size increases along with aging process, then decreases at the advanced aging stage (≥24 months in mice and ≥70 years in humans) [61, 62]. Similarly, brown adipocytes also manifest enlarged diameter and increased lipid droplet size with age in mice [63]. There is evidence that 3T3-L1 adipocytes volume gradually increases after induced maturation [64]. Moreover, aged mature adipocytes are characterized by the smaller dislocated nuclei and a large central lipid droplet (LD) surrounded by smaller ones [64]. Adipose tissues plasticity is impaired along with the progression of aging process as well. The ability of preadipocytes to replicate and differentiate into mature white or brown adipocytes declines with age, as manifested by the decrease of expression for adipogenic transcription factors PPAR-γ and C/EBP-α [65, 66]. Aging is associated with decreased lipid storage, fatty acid β-oxidation, and endocrine functions in white adipocyte. Moreover, the thermogenic capacity of BAT is reduced with age and coupled with downregulation of UCP1 expression as well [56]. Moreover, lipids are redistributed outside of the fat pool, accumulating in the liver, bone marrow, skeletal muscle, and other ectopic sites in old age. AT not only undergoes dramatic redistribution, but also couples with microenvironmental changes during the course of aging. In addition, mature adipocytes, progenitor cells, immune cells, and endothelial cells gradually senesce at different levels with aging in the heterogeneous and complex adipose tissue.

Senescent adipocytes exhibit a senescence-associated secretory phenotype (SASP) that includes a multitude of pro-inflammatory cytokines and chemokines triggering secondary senescence in neighboring cells [67]. Senescent cell accumulation in adipose tissue with advancing age results in both local and systemic dysfunction. P16-positive cells isolated from mouse inguinal adipose tissue exhibit high IL-6 expression and damage the function of adipocytes and impair insulin sensitivity in adipose tissue [66, 68]. Specifically, the accumulation of senescent preadipocytes and infiltrated immune cells, and increased pro-inflammatory cytokines perturb the microenvironment in AT, attenuating the lipid-handling capability of adipocytes, which then impairs adipogenesis and β-oxidation conveying higher risk of FFA-mediated lipotoxicity [37, 69, 70]. As such, the irreducible FFA and inordinate profile of adipokines produced by senescent adipocytes in turn increase the infiltration of inflammatory macrophages and other immune cells [71-73]. Indeed, the percentage of macrophages is positively correlated with age in human omental AT [74, 75]. In addition to macrophages, accumulation of neutral killer (NK) cells, neutrophils, eosinophils, mast cells, dendritic cells, and lymphocytes in AT exacerbate immune competence by promoting inflammasome activation and formation of crown-like structures [76, 77]. Likewise, inappropriate adipokines derived from senescent adipocytes and infiltrated immune cells affect the production of insulin and glucagon from the pancreas, leading to high blood glucose and insulin resistance, central obesity, dyslipidemia, and hypertension [78].

More importantly, aging is associated with a decline in preadipocyte proliferation and differentiation, which then prevents adipogenesis and subsequent tissue replacement and regeneration [79-81]. In particular, adipose tissue-derived mesenchymal stem cells (AT-MSCs) from elderly subjects are featured by the increased expression of senescence-related genes and severely reduced beiging capability [82]. The loss of BAT mass coupled with reduced thermogenic capacity is caused by the conversion of brown into white-like adipocytes along with defective proliferation of brown adipogenic progenitor cells during aging [83, 84]. Interestingly, inhibition of the senescent signaling pathway p38/MAPK-p16INK4a in adipose progenitor cells restores the beiging process and improves insulin resistance in aged individuals or mice [85]. In sharp contrast, activation of this particular pathway in young subjects accelerates preadipocyte senescence and prevents beiging induction [38]. Collectively, dramatic fat redistribution, irreducible lipotoxicity, excessive inflammation, and defective beiging are typical characteristics relevant to AT aging (Fig. 1).
Figure 1. The dysfunction of adipose tissue during aging. Aging leads to the redistribution of adipose tissue and reduces the ability of adipose precursor cells to differentiate into mature adipocytes [153, 170]. The senescence-associated secretory phenotype (SASP) of senescent adipocytes impairs the function of pancreatic islet, liver and skeletal muscle, aggravating obesity and insulin resistance with age. Senescent adipocytes secrete a multitude of pro-inflammatory cytokines and chemokines triggering immune cell infiltration. Increased infiltrated cells and inflammatory factors (IL-6, IL-1β, TNF-α) [23, 24, 26], and decreased protective adipocytokines (adiponectin, leptin, FGF21, CXCL14) lead to systemic insulin resistance, and obesity [33, 102, 171].

DNA methylation regulates the functional decline in aging white adipocytes

Upon the development of high-throughput technologies for the analysis of genome-wide DNAm levels, a large number of site-specific DNAm patterns had been characterized [52, 86]. Therefore, DNAm has now been recognized as having great potential as a biomarker for the aging process [87, 88]. Apparently, numerous studies have observed age-related methylation patterns associated with the function of adipocytes. However, it is still a challenge to identify more critical genes and pathways that are regulated by DNAm during the course of aging process in adipocytes before its application as a biomarker in clinical settings.

Over the past decade, studies have shown that DNAm comprises a key epigenetic machinery regulating the developmental processes and homeostasis of energy expenditure and storage in white adipocytes [89–91]. Increased methylation levels in the 3’ untranslated region and genomes relative to the promoter region are observed in adipose tissue from obese women [92]. Even omental and subcutaneous adipose tissue show significant differential methylation profiles under the influence of external environment [92, 93]. Whole-genome DNAm analysis further confirms that the thrust of genes or genomic regional CpG DNAm pattern changes are noted in white adipocytes with aging [94, 95]. For example, methylation of the master adipogenic regulator Ppar-γ promoter region inhibits its transcription and translation, which contributes to the pathogenesis of metabolic complications during aging [96, 97]. Consistently, the adipogenic activity of white adipocytes declines with age in subcutaneous AT, coupled with a decreased level of PPAR-γ, leading to AT redistribution, and insulin resistance [98, 99]. Interestingly, obesity induces methylation of the Ppar-γ promoter in visceral AT from diabetic mice, causing a concomitant decrease in mRNA expression compared to that in normal mice [100]. In addition, the paracrine effects of senescent white adipocytes also trigger systemic inflammation, insulin resistance and senescence in the distally regulated organs.

Aging disrupts the secretion and synthesis of adipokines from white adipocytes, some of which are modulated by DNAm [101]. Adiponectin, an insulin-sensitizing and anti-inflammatory adipokine, has been implicated in longevity signaling pathways, including AMPK, SIRT1, and PGC-1α [61], which exhibits a low circulating levels in elderly individuals [102]. In fact, methylation in the AdipoQ promoter represses adiponectin expression in WAT [103]. Additionally, adiponectin is hypermethylated in the promoter region.
under obese conditions [28, 103-106]. Similarly, the peptide hormone leptin, which mediates adipose tissue–brain communication to reduce food intake and body weight [107, 108], is also essential for developmentally induced beige adipocyte formation and white adipocyte browning [109-111]. In fact, the function of adipose tissue declines as the progression of aging process, which is also coupled with the change of leptin level. In particular, the frail elderly is featured by the low circulating levels of leptin as compared to the healthy counterparts [112, 113], indicating that higher leptin levels may serve as a hallmark to prevent systematic senescence, in which adipose tissue senescence is a major characteristic feature. More importantly, the expression of leptin is tightly controlled by DNA methylation [114], supporting that DNA methylation affects adipocyte senescence. Taken together, these findings suggest that altered DNA methylation disorganizes adipogenesis and the synthesis of adipoines in white adipocytes, predisposing to the initiation and progression of aging process (Fig. 2).

Figure 2. Effects of cellular DNA methylation on adipocytes senescence. Accumulated environmental factors and irreversible aging lead to changes in methylation patterns in adipocytes. Pathological increases in methylation levels of the promoter in \( \text{Ppar}-\gamma \) [100], \( \text{AdipoQ} \) [103], and \( \text{Lep} \) [114] result in white adipocyte glucose and lipid metabolism disorders, which further aggravate insulin resistance, obesity, and inflammation during aging. The promoter region of \( \text{PRDM16} \) and the enhancer region of \( \text{UCP1} \) tend to be hypermethylated during cellular senescence, leading to loss of beige adipose tissue and thermogenic properties of brown adipocytes [119, 123]. Impaired beige fat biogenesis and a transition from beige to white adipocytes positively correlate with fat inflammation and hyperinsulinemia. The hypomethylation of the promoter of senescence relevant genes (\( p21 \), \( p16 \)) and hypermethylation of the \( \text{TERT} \) promoter accelerate adipose progenitor cellular senescence and exhaustion [172, 173].
The role of DNA methylation in adipocytes during aging

The implication of DNA methylation in the senescence of brown and beige adipocytes

In the former scenario, there is an explicit relevance between metabolic disease and the loss of metabolically active BAT with aging, while the molecular circadian mechanisms remain obscure due to the limitation of current detective technologies. Although great strides in research have demonstrated that the production of growth hormone, estrogens, and androgens may positively modulate the activity of BAT [115], the detailed cellular switches underlying these effects remain to be elucidated. Recent studies have revealed that DNAm events play a critical role in regulating thermogenic and developmental gene expression in beige and brown adipocytes.

Indeed, there is feasible evidence that the loss of BAT and decreases in the beiging ability of AT are likely linked to the altered DNAm. For example, PR domain containing 16 (PRDM16) is an essential transcription factor in regulating the differentiation and development of brown and beige adipocytes [116-118]. However, DNA demethylation of CpG islands in the Prdm16 promoter, likely mediated by TET proteins, is required for its expression [119, 120], by which demethylation of the Prdm16 promoter improves brown/beige adipogenic capacity and alleviates obesity in aged mice challenged with high-fat diet [121]. Similarly, DNA methylation may also regulate transcriptional changes in genes involved in beige and brown adipose development and thermogenic activity. BAT thermogenic function is impaired during aging as manifested by the loss of UCP1, a unique mitochondrial marker [122]. Specifically, DNAm regulates UCP1 expression by altering the methylation levels of the Ucp1 regulatory sequence elements, and demethylation of the Ucp1 enhancer augments its expression in brown adipose tissue [123]. In contrast, the receptor-interacting protein of 140 kDa (RIP140) recruits DNA methyltransferases into the site of the Ucp1 enhancer, by which it promotes methylation of the Ucp1 enhancer to silence its expression [124, 125]. Studies in our group further revealed that senescent brown or beige adipocytes are featured by the changes DNAm levels and/or patterns, coupled with an impaired capability for energy expenditure (unpublished data). Given that alterations in the gene expression profile induced by DNA methylation during aging may be the key node of age-related impairments and diseases, we therefore assume that age-related alteration in DNAm may directly cause changes in the transcriptional landscape in charge of thermogenic adipocyte regenerative capacity and mitochondrial energy metabolism (Fig. 2).

DNA methylation in the senescence of adipose progenitor cells

Cellular senescence disrupts the dynamic balance in mesenchymal stem cells (MSCs), and thus impairing their therapeutic potential to differentiate into functional cells [126, 127]. Similarly, adipocytes developed from senescent preadipocytes exhibit reduced lipogenic capacity, resulting in glucose intolerance. Additionally, excessive accumulation of senescent progenitor cells in aging tissues triggers the generation of SASP pro-inflammatory cytokines, which strongly impedes the renewal and repair of injured tissues [66, 128-130]. Recent clinical trials have demonstrated a promising result that the senolytics, Dasatinib plus Quercetin (D+Q), directly eliminates senescent cells, which alleviates systemic SASP factors in human AT [131]. However, the mechanisms underlying age-related functional declines in preadipocytes are yet to be fully elucidated.

Comparative analysis of human MSCs from young and elderly donors revealed highly significant DNAm differences within the specific CpG sites of genes involved in cell differentiation [132]. Furthermore, the expression of genes relevant to differentiation including C/ebp-α and Ppar-γ, is decreased in preadipocytes with increasing age. A genome-wide analysis of DNA methylation of human preadipocytes compared to that of mature adipocytes revealed that 2,701 genes were hypomethylated and 1,070 genes were hypermethylated after adipocyte differentiation [133]. In fact, aging results in the deterioration of human AT-MSCs primarily through increasing DNAm levels, which induces oxidative stress and mitochondrial dysfunction [134-136]. Interestingly, L-carnitine efficiently decreases the percentage of senescent cells in AT-MSCs partially by modifying the methylation status of the human telomerase reverse transcriptase (hTERT) promoter region [137-139]. The hTERT promoter methylation status determines the expression of hTERT and telomerase activity [137, 140] (Fig. 2).

Age-related DNAm patterns also appear to be an important factor to maintain the healthy differentiation of adipose progenitor cells as well. In particular, a significant difference in terms of DNAm patterns was characterized between adipose progenitor cells originated from young and aged subjects as well as mice (unpublished data). The compromise in replication and differentiation of preadipocytes has been shown to drive insulin resistance by limiting plasticity of adipose tissue. However, considerable investigation is required to determine the molecular mechanisms associated with DNA methylation underlying the alterations in adipogenic phenotypes.
Obesity dysregulates DNA methylation to promote the adipocyte aging process

Weight gain and the accumulation of adipose tissue increase the risk of a variety of age-related diseases, such as cardiovascular disease, and type 2 diabetes. Indeed, aging and obesity seem to share the same disease mechanisms, and one exacerbates the other [80, 141, 142]. An increased burden of senescent cells is observed in adipose tissue from obese individuals compared to lean age-matched controls [80]. In addition, subcutaneous adipose tissue from obese patients exhibits shorter telomeres [143]. Moreover, DNA methylation status displays specific tissue changes under the influence of age and obesity induced by high-calorie diets [92, 144]. It has been noted that peripheral blood from obese subjects is characterized by decreased DNA methylation compared to lean individuals during the course of aging [145]. This phenomenon could result from the limited energy intake coupled with the induction of DNMT1 expression, leading to de novo methylation [146].

Obesity affects genomic DNA methylation in AT, which then exacerbates the aging process of adipocytes and impairs their function [71, 86, 147-149]. Obesity aggravates senescence and dysfunction of adipocytes by modulating the methylation levels of genes in insulin secretion and energy metabolic pathways [150]. A higher potency to induce DNA hypermethylation in genes associated with energy expenditure than in genes relevant to energy storage has been observed in epididymal WAT challenged by HFD [90]. For instance, CpG methylation of the Plin1 promoter in adipocytes from obese women is higher than that in adipocytes from lean women [151]. Increased BMI is associated with increased methylation at the hypoxia inducible transcription factor (Hif3a) locus in human adipose tissue [152], while DNA methylation in intron 1 of Cpt1a, which encodes the enzyme carnitine palmitoyltransferase 1α, is inversely associated with waist circumference [153]. One reason for the age-related decrease in lipogenic activity is the lower expression of fatty acid synthase (FASN), an obligatory enzyme for the cellular synthesis of long-chain fatty acids [154, 155]. Methylation levels of Fasn in the promoter and first exon determine its expression. Furthermore, aging promotes adipose tissue as an energy sensor that is extremely susceptible to overnutrition, for which DNA methylation would provide a molecular link between aging and obesity.

Conclusion and perspective

DNA methylation has now been recognized to play a critical role in the pathogenesis of age-related functional decline. Some CpG sites are highly correlated with aging, in which a small number of CpG sites are able to accurately predict the age of donors [86]. These DNA methylation sites have remarkably strong correlations with chronological age that could be predicted from the DNA methylation patterns of blood, saliva, buccal swab samples [156], glial cells and neurons [157]. Despite these advancements, the impact of DNA methylation on adipocyte aging process is yet to be fully elucidated, which deserves further investigations. Of note, other than DNA methylation, additional epigenetic mechanisms such as post-translational modification of histones or non-histone proteins are likely involved in the regulation of aging process as well. For example, the protein demethylase KDM1A maintains beige adipocytes by decreasing H3K9me2 levels to enhance PPAR-α expression [158].

There is convincing evidence that DNA methylation represents a bridge linking nutritional insults and genes, thereby being involved in developmental and senescent processes in AT. Due to the reversible nature of epigenetic programming, therapeutic interventions to reverse deleterious epigenetic changes would be promising to prevent relevant age-related metabolic disorders. In particular, restoration of the DNA methylation patterns in AT has been suggested to recover its thermogenesis properties during aging. Although we now have more understanding regarding the effects of DNA methylation on adipose aging, how environmental confounders, particularly overnutrition, induce global or gene-specific DNA methylation changes (e.g., methylation levels and/or patterns) and contribute to the initiation and progression of adipose dysfunction and aging remains largely unknown. It is indispensable to identify a consistent, reliable, and independent signature of DNA methylation across individuals of advanced age. Therefore, elucidation of the mechanisms underlying cellular senescence in adipocytes would have great potential for the development of approaches for increasing longevity and improving precision health.

Currently, the advancement of whole-genome methylation sequencing data would provide us the feasibility to identify comprehensive DNA methylation biomarkers for the adipose aging process and use such DNA methylation mechanisms for treatment or diagnosis of adipocyte senescence earlier. However, the critical issue is the development of approaches to modulate specific DNA methylation machinery (e.g., modulating the methylation levels or patterns for a specific gene or a set of specific genes) that corresponds to the aging phenotype in adipocytes. Therefore, the development of gene-specific DNA methylation modulators and optimization of their dosages for the treatment of adipocyte senescence would be a major focus and worthwhile for future investigation. Likewise, DNA methyltransferase inhibitors, including azacitidine (5’-AZA) [159], decitabine [160, 161], zebularine [162, 163], and RG108 [161], have already been applied to treat various types of cancer, systemic sclerosis (SSc) and...
myelodysplastic syndrome (MDS) [164, 165]. However, severe side effects attenuated their application in clinical settings. In sharp contrast, the “readers” for DNA methylome (i.e., the methyl-CpG-binding domain proteins) are featured by the expression in a cell- or tissue-type dependent manner along with induction under diseased condition. More importantly, those MBD proteins themselves do not affect DNAm but interpret the effect of DNAm on target gene transcription [90, 166]. Particularly, MBD2 appears to be dispensable for biological processes under physiological condition [167-169]. Therefore, therapeutic strategies aimed at modulating the expression and/or functionality of DNAm readers, such as MBD2, could be a viable approach to prevent or treat adipocyte aging in clinical settings.

Acknowledgments

Our study was supported by the National Natural Science Foundation of China (81530024, 91749207, 81920108009, 82070808, 81770823 and 81670729), the Ministry of Science and Technology (2016YFC1305002 and 2017YFC1309603), NHC Drug Discovery Program (2017ZX09304022-07), the Department of Science and Technology of Hubei State (2017ACA096), the Integrated Innovative Team for Major Human Disease Programs of Tongji Medical College, Huazhong University of Science and Technology, and the Innovative Funding for Translational Research from Tongji Hospital.

Conflict of interest

The authors declare that they have no conflict of interest.

References

[1] Schoettl T, Fischer IP, Ussar S (2018). Heterogeneity of adipose tissue in development and metabolic function. J Exp Biol, 221.
[2] White U, Ravussin E (2019). Dynamics of adipose tissue turnover in human metabolic health and disease. Diabetologia, 62:17-23.
[3] Lafontan M, Langin D (2009). Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res, 48:275-297.
[4] DeFronzo RA (2004). Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract Suppl:9-21.
[5] Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R, et al. (1989). Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest, 84:1663-1670.
[6] Kirkland JL, Tchkonia T, Pirtskhalava T, Han J, Karagiannides I (2002). Adipogenesis and aging: does aging make fat go MAD? Exp Gerontol, 37:757-767.
[7] Marcus RL, Addison O, Kidde JP, Dibble LE, Lastayo PC (2010). Skeletal muscle fat infiltration: impact of age, inactivity, and exercise. J Nutr Health Aging, 14:362-366.
[8] Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, et al. (2012). Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol, 57:1305-1311.
[9] Cannon B, Nedergaard J (2004). Brown adipose tissue: function and physiological significance. Physiol Rev, 84:277-359.
[10] Fedorenko A, Lishko PV, Kirichok Y (2012). Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria. Cell, 151:400-413.
[11] Whittle AJ, Carobbio S, Martins L, Slawik M, Hondares E, Vazquez MJ, et al. (2012). BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell, 149:871-885.
[12] Caron A, Labbe SM, Carter S, Roy MC, Lecomte R, Ricquier D, et al. (2017). Loss of UCP2 impairs cold-induced non-shivering thermogenesis by promoting a shift toward glucose utilization in brown adipose tissue. Biochimie, 134:118-126.
[13] Cohen P, Levy JD, Zhang Y, Frontini A, Kolodin DP, Svensson KJ, et al. (2014). Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell, 156:304-316.
[14] Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, Giang AH, et al. (2012). Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell, 150:366-376.
[15] Ishibashi J, Saele P (2010). Medicine. Beige can be slimming. Science, 328:1113-1114.
[16] Giralt M, Villarroya F (2013). White, brown, beige/brite: different adipose cells for different functions? Endocrinology, 154:2992-3000.
[17] Min SY, Kady J, Nam M, Rojas-Rodriguez R, Berkenwald A, Kim JH, et al. (2016). Human ‘beige/brite’ adipocytes develop from capillary networks, and their implantation improves metabolic homeostasis in mice. Nat Med, 22:312-318.
[18] Fan H, Zhang Y, Zhang J, Yao Q, Song Y, Shen Q, et al. (2020). Cold-Inducible KIf9 Regulates Thermogenesis of Brown and Beige Fat. Diabetes, 69:2603-2618.
[19] Oguri Y, Shinoda K, Kim H, Alba DL, Bolus WR, Wang Q, et al. (2020). CD81 Controls Beige Fat Progenitor Cell Growth and Energy Balance via FAK Signaling. Cell, 182:563-587 e520.
[20] Choi HM, Doss HM, Kim KS (2020). Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. Int J Mol Sci, 21.
[21] Matsubara M, Maruoka S, Katayose S (2002). Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol, 147:173-180.
[22] Guo K, McMinn JE, Ludwig T, Yu YH, Yang G, Chen L, et al. (2007). Disruption of peripheral leptin signaling in mice results in hyperleptinemia without...
associated metabolic abnormalities. Endocrinology, 148:3987-3997.

[23] Wueest S, Laesser CI, Boni-Schnetzler M, Item F, Lucchini FC, Borsigova M, et al. (2018). IL-6-Type Cytokine Signaling in Adipocytes Induces Intestinal GLP-1 Secretion. Diabetes, 67:36-45.

[24] Unamuno X, Gomez-Ambrosi J, Ramirez B, Rodriguez A, Becerril S, Valenti V, et al. (2021). NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling. Cell Mol Immunol, 18:1045-1057.

[25] Rajbhandari P, Thomas BJ, Feng AC, Hong C, Wang J, Vargas L, et al. (2018). IL-10 Signaling Remodels Adipose Chromatin Architecture to Limit Thermogenesis and Energy Expenditure. Cell, 172:218-233 e217.

[26] Castillo-Madrigal R, Gil-Iturbe B, Sainz N, Moreno-Aliaga MJ, Lostao MP (2019). Basolateral presence of the proinflammatory cytokine tumor necrosis factor-alpha and secretions from adipocytes and macrophages reduce intestinal sugar transport. J Cell Physiol, 234:4352-4361.

[27] Chang CH, Chang YT, Tseng TH, Wang CJ (2018). Mulberry leaf extract inhibit hepatocellular carcinoma cell proliferation via depressing IL-6 and TNF-alpha derived from adipocyte. J Food Drug Anal, 26:1024-1032.

[28] Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB (2006). Adiponectin regulates sperm motility and spermatogenesis. Reprod Biomed Online, 33:690-702.

[29] Lopez T, Villarroya J, Cereijo R, Gavalda et al. (2018). Basolateral inflammatory cytokine signaling in adipocytes and macrophages: potential impact on the metabolic syndrome. Diabetes Obes Metab, 8:264-274.

[30] Zhang M, Wang C, Wu J, Ha X, Deng Y, Zhang X et al. (2018). The Effect and Mechanism of KLF7 in the TLR4/NF-kappaB/IL-6 Inflammatory Signal Pathway of Adipocytes. Mediators Inflamm, 2018:1756494.

[31] Acosta JR, Tavira B, Douagi I, Kulyte A, Arner P, Ryden M, et al. (2019). Human-Specific Function of IL-10 in Adipose Tissue Linked to Insulin Resistance. J Clin Endocrinol Metab, 104:4552-4562.

[32] Villarroya J, Cereijo R, Gavalda-Navarro A, Peyrou M, Giralt M, Villarroya F (2019). New insights into the secretory functions of brown adipose tissue. J Endocrinol, 243:R19-R27.

[33] Cereijo R, Gavalda-Navarro A, Cairo M, Quezada-Lopez T, Villarroya J, Moron-Ros S, et al. (2018). CXCL14, a Brown Adipokine that Mediates Brown-Fat-to-Macrophage Communication in Thermogenic Adaptation. Cell Metab, 28:750-763 e756.

[34] Kong X, Yao T, Zhou P, Kazak L, Tenen D, Lyubetskaya A, et al. (2018). Brown Adipose Tissue Controls Skeletal Muscle Function via the Secretion of Myostatin. Cell Metab, 28:631-643 e633.

[35] Deshmukh AS, Pejs I, Beaudry JL, Jespersen NZ, Nielsen CH, Ma T, et al. (2019). Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine. Cell Metab, 30:963-975 e967.

[36] Slawik M, Vidal-Puig AJ (2006). Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev, 5:144-164.

[37] Cartwright MJ, Tchkonia T, Kirkland JL (2007). Aging in adipocytes: potential impact of inherent, depot-specific mechanisms. Exp Gerontol, 42:463-471.

[38] Berry DC, Jiang Y, Arpke RW, Close EL, Uchida A, Reading D, et al. (2017). Cellular Aging Contributes to Failure of Cold-Induced Beige Adipocyte Formation in Old Mice and Humans. Cell Metab, 25:481.

[39] Chen BH, Marioni RE, Colicino E, Peters MJ, Ward-Caviness CK, Tsai PC, et al. (2016). DNA methylation-based measures of biological age: meta-analysis predicting time to death. Aging (Albany NY), 8:1844-1865.

[40] Lopez-Onin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013). The hallmarks of aging. Cell, 153:1194-1217.

[41] Reik W (2007). Stability and flexibility of epigenetic gene regulation in mammalian development. Nature, 447:425-432.

[42] Uysal F, Ozturk S, Akkoyunlu G (2017). DNMT1, DNMT3A and DNMT3B proteins are differently expressed in mouse oocytes and early embryos. J Mol Histol, 48:417-426.

[43] Uysal F, Akkoyunlu G, Ozturk S (2016). DNA methyltransferases exhibit dynamic expression during spermatogenesis. Reprod Biomed Online, 33:690-702.

[44] Zou J, Wu Y, Xiao B, Guo X, Zheng Q, Wu B (2019). Age-related Changes in the Global DNA Methylation Profile of Oligodendrocyte Progenitor Cells Derived from Rat Spinal Cords. Curr Med Sci, 39:67-74.

[45] Rao X, Zhong J, Zhang S, Zhang Y, Yu Q, Yang P, et al. (2011). Loss of methyl-CpG-binding domain protein 2 enhances endothelial angiogenesis and protects mice against hind-limb ischemic injury. Circulation, 123:2964-2974.

[46] Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bромage H, et al. (1999). MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet, 23:58-61.

[47] Dhasarathy A, Wade PA (2008). The MBD protein family-reading an epigenetic mark? Mutat Res, 647:39-43.

[48] Dhasarathy A, Wade PA (2008). The MBD protein family-reading an epigenetic mark? Mutat Res, 647:39-43.

[49] Bochtler M, Kolano A, Xu GL (2017). DNA demethylation pathways: Additional players and regulators. Bioessays, 39:1-13.

[50] He Y, Ecker JR (2015). Non-CG Methylation in the Human Genome. Annu Rev Genomics Hum Genet, 16:55-77.

[51] Bird A (2002). DNA methylation patterns and epigenetic memory. Genes Dev, 16:6-21.

[52] Bell CG, Lowe R, Adams PD, Baccarelli AA, Beck S,
BELL JT, et al. (2019). DNA methylation aging clocks: challenges and recommendations. Genome Biol, 20:249.

[53] Coleman SR, Grover R (2006). The anatomy of the aging face: volume loss and changes in 3-dimensional topography. Aesthet Surg J, 26:S4-9.

[54] Kruglikov IL, Scherer PE (2016). Skin aging: are adipocytes the next target? Aging (Albany NY), 8:1457-1469.

[55] Saely CH, Geiger K, Drexel H (2012). Brown versus white adipose tissue: a mini-review. Gerontology, 58:15-23.

[56] Rogers NH, Landa A, Park S, Smith RG (2012). Aging leads to a programmed loss of brown adipocytes in murine subcutaneous white adipose tissue. Aging Cell, 11:1074-1083.

[57] Graja A, Gohlke S, Schulz TJ (2019). Aging of Brown and Beige/Brite Adipose Tissue. Handb Exp Pharmacol, 251:55-72.

[58] Symonds ME (2013). Brown adipose tissue growth and development. Scientifica (Cairo), 2013:305763.

[59] Ponrartana S, Hu HH, Gilsanz V (2013). On the relevance of brown adipose tissue in children. Ann N Y Acad Sci, 1302:24-29.

[60] Persichetti A, Sciuto R, Rea S, Basciani S, Lubrano C, Mariani S, et al. (2013). Prevalence, mass, and glucose-uptake activity of (1)(8)F-FDG-detected brown adipose tissue in humans living in a temperate zone of Italy. PLoS One. 8:e63391.

[61] Miller KN, Burbans MS, Clark JP, Howell PR, Polewski MA, DeMuth TM, et al. (2017). Aging and caloric restriction impact adipose tissue, adiponectin, and circulating lipids. Aging Cell, 16:497-507.

[62] Von Bank H, Kirch C, Simcox J (2021). Aging adipose: depot location dictates age-associated expansion and dysfunction. Ageing Res Rev, 72.

[63] Goncalves LF, Cummins P, Chan G, Mariani S, et al. (2013). Altered expression of C/EBP family members results in decreased adipogenesis with aging. Am J Physiol Regul Integr Comp Physiol, 280:R1772-1780.

[64] Xu M, Palmer AK, Ding H, Weivoda MM, Pirskhalava T, White TA, et al. (2015). Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife, 4:e12997.

[65] Nelson G, Wordsworth J, Wang C, Jurk D, Lawless C, Martin-Ruiz C, et al. (2012). A senescent cell bystander effect: senescence-induced senescence. Aging Cell, 11:345-349.

[66] Baker DJ, Wijskate T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al. (2011). Clearance of p16Ink4a-positive senescent cells delays aging-associated disorders. Nature, 479:232-236.

[67] Guo W, Pirskhalava T, Tchkonia T, Xie W, Thomou T, Han J, et al. (2007). Aging results in paradoxical susceptibility of fat cell progenitors to lipotoxicity. Am J Physiol Endocrinol Metab, 292:E1041-1051.

[68] Wasko RR, Horsley V (2019). Thin Skinned: Aged Adipocyte Atrophy Impacts Innate Immunity. Trends Immunol, 40:175-177.

[69] Zamboni M, Rossi AP, Fantin F, Zamboni G, Chirumbolo S, Zoico E, et al. (2014). Adipose tissue, diet and aging. Mech Ageing Dev, 136:129-137.

[70] Karagiannides I, Thomou T, Tchkonia T, Pirskhalava T, Kypreos KE, Cartwright A, et al. (2006). Increased CUG triplet repeat-binding protein-1 predisposes to impaired adipogenesis with aging. J Biol Chem, 281:23025-23033.

[71] Martyniak K, Masternak MM (2017). Changes in adipose tissue cellular composition during obesity and aging as a cause of metabolic dysregulation. Exp Gerontol, 94:59-63.

[72] Harman-Boehm I, Bluhser M, Redel H, Sion-Vardy N, Ovadia S, Avinoach E, et al. (2007). Macrophage infiltration into omental versus subcutaneous fat across different populations: Effect of regional adiposity and the comorbidities of obesity. Journal Of Clinical Endocrinol & Metabolism, 92:2240-2247.

[73] Jeschows AE, Anwar S, Barzilai N, Rosenberg D (2007). Macrophage accumulation in visceral and subcutaneous adipose tissue correlates with age. Journal Of Allergy And Clinical Immunology, 119:S179-S179.

[74] Trim W, Turner GE, Thompson DC (2018). Parallels in Immunometabolic Adipose Tissue Dysfunction with Aging and Obesity. Front Immunol, 9:169.

[75] De Carvalho FG, Justus JN, Freitas EC, Kershaw EE, Sparks LM (2019). Adipose Tissue Quality in Aging: How Structural and Functional Aspects of Adipose Tissue Impact Skeletal Muscle Quality. Nutrients, 11.

[76] Guilherme A, Virbasius JV, Puri V, Czech MP (2008). Anterior hypothalamic dysfunction in obesity: links to adipocyte dysfunction and leptin resistance. J Physiol Endocrinol Metab, 292:E1041.

[77] Mitteda M, Martinelli FA, Conti F, De Biasi G, Porcellini A, et al. (2010). Fat tissue, aging, and cellular senescence. Aging Cell, 9:667-684.

[78] Sepe A, Tchkonia T, Thomou T, Zamboni M, Kirkland JL (2011). Aging and regional differences in fat cell progenitors - a mini-review. Gerontology, 57:66-75.

[79] Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scialone H, et al. (2010). Fat tissue, aging, and cellular senescence. Aging Cell, 9:667-684.

[80] Maredziak M, Marycz K, Tomaszewski KA, Kornicka K, Henry BM (2016). The Influence of Aging on the Regenerative Potential of Human Adipose Derived Mesenchymal Stem Cells. Stem Cells Int, 2016:2152435.

[81] Alt EU, Senst C, Murthy SN, Slakey DP, Dunip CL, Chaffin AE, et al. (2012). Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res, 8:215-225.

[82] Gohlke S, Zagory V, Cuadros Inostroza A, Meret M,
Mancini C, Japtok L, et al. (2019). Identification of functional lipid metabolism biomarkers of brown adipose tissue aging. Mol Metab, 24:1-17.

[84] Graja A, Schulz TJ (2015). Mechanisms of aging-related impairment of brown adipocyte development and function. Gerontology, 61:211-217.

[85] Berry DC, Jiang Y, Arpke RW, Close EL, Uchida A, Reading D, et al. (2017). Cellular Aging Contributes to Failure of Cold-Induced Beige Adipocyte Formation in Old Mice and Humans. Cell Metab, 25:166-181.

[86] Jones MJ, Goodman SJ, Korb MS (2015). DNA methylation and healthy human aging. Aging Cell, 14:924-932.

[87] Lim U, Song MA (2018). DNA Methylation as a Biomarker of Aging in Epidemiologic Studies. Methods Mol Biol, 1856:219-231.

[88] Salameh Y, Bejaoui Y, El Hajj N (2020). DNA Methylation Biomarkers in Aging and Age-Related Diseases. Front Genet, 11:171.

[89] Sonne SB, Yadav R, Yin G, Dalgaard MD, Myrmel LS, Gupta R, et al. (2017). Obesity is associated with depot-specific alterations in adipocyte DNA methylation and gene expression. Adipocyte, 6:124-133.

[90] Cheng J, Song J, He X, Zhang M, Hu S, Zhang S, et al. (2016). Loss of Mbd2 Protects Mice Against High-Fat Diet-Induced Obesity and Insulin Resistance by Regulating the Homeostasis of Energy Storage and Expenditure. Diabetes, 65:3384-3395.

[91] Dhasarathy A, Roemisch JN, Claycombe KJ (2017). Influence of maternal obesity, diet and exercise on epigenetic regulation of adipocytes. Mol Aspects Med, 54:37-49.

[92] Benton MC, Johnstone A, Eccles D, Harman B, Hayes MT, Lea RA, et al. (2015). An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. Genome Biol, 16:8.

[93] Gehrke S, Brueckner B, Schepky A, Klein J, Iwen A, Bosch TC, et al. (2013). Epigenetic regulation of depot-specific gene expression in adipose tissue. PLoS One, 8:e82516.

[94] Bell JT, Tsai PC, Yang TP, Pidsley R, Nisbet J, Glass D, et al. (2012). Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population. PLoS Genet, 8:e1002629.

[95] Unnikrishnan A, Freeman WM, Jackson J, Wren JD, Porter H, Richardson A (2019). The role of DNA methylation in epigenetics of aging. Pharmacol Ther, 195:172-185.

[96] Haramizu S, Ota N, Hase T, Murase T (2011). Aging-associated changes in physical performance and energy metabolism in the senescence-accelerated mouse. J Gerontol A Biol Sci Med Sci, 66:646-655.

[97] Argmann C, Dobrin R, Heikkinen S, Auburtin A, Pouilly L, Cock TA, et al. (2009). Ppargamma2 is a key driver of longevity in the mouse. PLoS Genet, 5:e1000752.

Mitterberger MC, Lechner S, Mattesich M, Zwerschke W (2014). Adipogenic differentiation is impaired in replicative senescent human subcutaneous adipose-derived stromal/progenitor cells. J Gerontol A Biol Sci Med Sci, 69:13-24.

Hammarstedt A, Gogg S, Hedjazifar S, Nerstedt A, Smith U (2018). Impaired Adipogenesis and Dysfunctional Adipose Tissue in Human Hypertrophic Obesity. Physiol Rev, 98:1911-1941.

Fujiki K, Kano F, Shiota K, Murata M (2009). Expression of the peroxisome proliferator activated receptor gamma gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes. BMC Biol, 7:38.

Ma X, Kang S (2019). Functional Implications of DNA Methylation in Adipose Biology. Diabetes, 68:871-878.

Gulcelik NE, Halil M, Ariogul S, Usman A (2013). Adipocytokines and aging: adiponectin and leptin. Minerva Endocrinol, 38:203-210.

Kim AY, Park YJ, Pan X, Shin KC, Kwak SH, Bussas AF, et al. (2015). Obesity-induced DNA hypermethylation of the adiponectin gene mediates insulin resistance. Nat Commun, 6:7585.

Liu M, Liu F (2014). Regulation of adiponectin multimerization, signaling and function. Best Pract Res Clin Endocrinol Metab, 28:25-31.

Liu Y, Sweeney G (2014). Adiponectin action in skeletal muscle. Best Pract Res Clin Endocrinol Metab, 28:33-41.

Lu Y, Fan C, Liang A, Fan X, Wang R, Li P, et al. (2018). Effects of SCFA on the DNA methylation pattern of adiponectin and resistin in high-fat-diet-induced obese male mice. Br J Nutr, 1-8.

Chong AC, Greendyk RA, Zeltsner LM (2015). Distinct networks of leptin- and insulin-sensing neurons regulate thermogenic responses to nutritional and cold challenges. Diabetes, 64:137-146.

Zhao S, Kusminski CM, Elmquist JK, Scherer PE (2020). Leptin: Less Is More. Diabetes, 69:823-829.

Dodd GT, Decherf S, Loh K, Simonds SE, Wiede F, Balland E, et al. (2015). Leptin and insulin act on POMC neurons to promote the browning of white fat. Cell, 160:88-104.

Wu R, Yu W, Fu L, Li F, Jing J, Cui X, et al. (2020). Postnatal leptin surge is critical for the transient induction of the developmental beige adipocytes in mice. Am J Physiol Endocrinol Metab, 318:E453-E461.

Xu Y, Wang N, Tan HY, Li S, Zhang C, Zhang Z, et al. (2020). Panax notoginseng saponins modulate the gut microbiota to promote thermogenesis and beige adipocyte reconstruction via leptin-mediated AMPKalpha/STAT3 signaling in diet-induced obesity. Theranostics, 10:11302-11323.

Hamrick MW (2017). Role of the Cytokine-like Hormone Leptin in Muscle-bone Crosstalk with Aging. J Bone Metab, 24:1-8.

Pareja-Galeano H, Santos-Lozano A, Sanchis-Gomar
F, Fiuza-Luces C, Garatecha N, Galvez BG, et al. (2017). Circulating leptin and adiponectin concentrations in healthy exceptional longevity. Mech Ageing Dev, 162:129-132.

[114] Melzner I, Scott V, Dorsch K, Fischer P, Wabitsch M, Bruderlein S, et al. (2002). Leptin gene expression in human preadipocytes is switched on by maturation-induced demethylation of distinct CpGs in its proximal promoter. J Biol Chem, 277:45420-45427.

[115] Valle A, Santandreu FM, Garcia-Palmer FJ, Roca P, Oliver J (2008). The serum levels of 17beta-estradiol, progesterone and triiodothyronine correlate with brown adipose tissue thermogenic parameters during aging. Cell Physiol Biochem, 22:337-346.

[116] He L, Tang M, Xiao T, Liu H, Liu W, Li G, et al. (2018). Obesity-Associated mir-199a/214 Cluster Inhibits Adipose Browning via PRDM16-PGC-1alpha Transcriptional Network. Diabetes. 67:2585-2600.

[117] Ohno H, Shinoda K, Spiegelman BM, Kajimura S (2012). PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab, 15:395-404.

[118] Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, et al. (2008). PRDM16 controls a brown fat/skeletal muscle switch. Nature, 454:961-967.

[119] Yang Q, Liang X, Sun X, Zhang L, Fu X, Rogers CJ, et al. (2015). Hydroxymethylcytosine in mouse ES cells and during differentiation. Nature, 437:398-402.

[120] Tian Q, Zhao J, Yang Q, Wang B, Deavila JM, Zhu MJ, et al. (2020). Dietary alpha-ketoglutarate promotes beige adipogenesis and prevents obesity in middle-aged mice. Aging Cell, 19:e13059.

[121] McDonald RB, Horwitz BA (1999). Brown adipose tissue thermogenesis during aging and senescence. J Bioenerg Biomembr, 31:507-516.

[122] Shore A, Karamitri A, Kemp P, Speakman JR, Lomax MA (2010). Role of Ucp1 enhancer methylation and chromatin remodelling in the control of Ucp1 expression in murine adipose tissue. Diabetologia, 53:1164-1173.

[123] Kiskinis E, Hallberg M, Christian M, Olofsson M, Dilworth SM, White R, et al. (2007). RIP140 directs histone and DNA methylation to silence Ucp1 expression in white adipocytes. EMBO J, 26:4831-4840.

[124] Christian M, Kiskinis E, Debevec D, Leonardsson G, White R, Parker MG (2005). RIP140-targeted repression of gene expression in adipocytes. Mol Cell Biol, 25:9383-9391.

[125] Duscher D, Rennert RC, Januszyk M, Anghel E, Maan ZN, Whittem AJ, et al. (2014). Aging disrupts cell subpopulation dynamics and diminishes the function of mesenchymal stem cells. Sci Rep, 4:7144.

[126] Noer A, Boquist AC, Collas P (2007). Dynamics of adipogenic promoter DNA methylation during clonal culture of human adipose stem cells to senescence. BMC Cell Biol, 8:18.

[127] Farr JN, Xu M, Weivoda MM, Monroe DG, Fraser DG, Onken JL, et al. (2017). Targeting cellular senescence prevents age-related bone loss in mice. Nat Med, 23:1072-1079.

[128] Justice JN, Gregory H, Tchkonia T, LeBrasseur NK, Kirkland JL, Kritchevsky SB, et al. (2018). Cellular Senescence Biomarker p16INK4a+ Cell Burden in Hid Adipose is Associated With Poor Physical Function in Older Women. J Gerontol A Biol Sci Med Sci, 73:939-945.

[129] Zhu Y, Armstrong JL, Tchkonia T, Kirkland JL (2014). Cellular senescence and the senescent secretory phenotype in age-related chronic diseases. Curr Opin Clin Nutr Metab Care, 17:324-328.

[130] Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Gjorgadze N, Hashmi SK, et al. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine, 47:446-456.

[131] Bork S, Pfister S, Witt H, Horn P, Korn B, Ho AD, et al. (2010). DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell, 9:54-63.

[132] Zhu JG, Xia L, Ji CB, Zhang CM, Zhu GZ, Shi CM, et al. (2012). Differential DNA methylation status between human preadipocytes and mature adipocytes. Cell Biochem Biophys, 63:1-15.

[133] Kornicka K, Marycz K, Maredziak M, Tomaszewski KA, Niepon J (2017). The effects of the DNA methyltransferases inhibitor 5-Azacytidine on ageing, oxidative stress and DNA methylation of adipose derived stem cells. J Cell Mol Med, 21:387-401.

[134] Bacalini MG, D’Aquila P, Marasco E, Nardini C, Montesanto A, Franceschi C, et al. (2017). The methylation of nuclear and mitochondrial DNA in ageing phenotypes and longevity. Mech Ageing Dev, 165:156-161.

[135] D’Aquila P, Bellizzi D, Passarino G (2015). Mitochondria in health, aging and diseases: the epigenetic perspective. Biogerontology, 16:569-585.

[136] Farahzadi R, Mesbah-Namin SA, Zarghami N, Fathi E (2016). L-carnitine Effectively Induces hTERT Gene Expression of Human Adipose Tissue-derived Mesenchymal Stem Cells Obtained from the Aged Subjects. Int J Stem Cells, 9:107-114.

[137] Farahzadi R, Fathi E, Mesbah-Namin SA, Zarghami N (2018). Anti-aging protective effect of L-carnitine as clinical agent in regenerative medicine through increasing telomerase activity and change in the hTERT promoter CpG island methylation status of adipose tissue-derived mesenchymal stem cells. Tissue Cell, 54:105-113.

[138] Mobarak H, Fathi E, Farahzadi R, Zarghami N, Javanmardi S (2017). L-carnitine significantly decreased aging of rat adipose tissue-derived mesenchymal stem cells. Vet Res Commun, 41:41-47.
The role of DNA methylation in adipocytes during aging

[140] Li JJ, Zheng PCJ, Wang YZ (2017). The correlations between DNA methylation and polymorphisms in the promoter region of the human telomerase reverse transcriptase (hTERT) gene with postoperative recurrence in patients with thyroid carcinoma (TC). World J Surg Oncol, 15:114.

[141] Ronn T, Volkov P, Gillberg L, Kokosar M, Perifikasiy A, Jacobsen AL, et al. (2015). Impact of age, BMI and HbA1c levels on the genome-wide DNA methylation and mRNA expression patterns in human adipose tissue and identification of epigenetic biomarkers in blood. Hum Mol Genet, 24:3792-3813.

[142] Bentley RA, Ross CN, O’Brien MJ (2018). Obesity, Metabolism, and Aging: A Multiscalar Approach. Prog Mol Biol Transl Sci, 155:25-42.

[143] Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. (2005). Obesity, cigarette smoking, and telomere length in women. Lancet, 366:662-664.

[144] Macartney-Coxson D, Benton MC, Blick R, Stubbs RS, Hagan RD, Langston MA (2017). Genome-wide DNA methylation analysis reveals loci that distinguish different types of adipose tissue in obese individuals. Clin Epigenetics, 9:48.

[145] Almen MS, Nilsson EK, Jacobsson JA, Kalinina I, Klovins J, Fredriksson R, et al. (2014). Genome-wide analysis reveals DNA methylation markers that vary with both age and obesity. Gene, 548:61-67.

[146] Chouliares L, van den Hove DL, Kenis G, Dela Cruz J, Lemmens MA, van Os J, et al. (2011). Caloric restriction attenuates age-related changes of DNA methyltransferase 3a in mouse hippocampus. Brain Behav Immun, 25:616-623.

[147] Guarasci F, D’Aquila P, Mandala M, Garasto S, Lattanzio F, Corsonello A, et al. (2018). Aging and nutrition induce tissue-specific changes on global DNA methylation status in rats. Mech Ageing Dev.

[148] Ahima RS (2009). Connecting obesity, aging and diabetes. Nat Med, 15:996-997.

[149] Conley SM, Hickson LJ, Kellogg TA, McKenzie T, Heimbach JK, Taner T, et al. (2020). Human Obesity Induces Dysfunction and Early Senescence in Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells. Front Cell Dev Biol, 8:197.

[150] Li W, Tang R, Ma F, Ouyang S, Liu Z, Wu J (2018). Folic acid supplementation alters the DNA methylation profile and improves insulin resistance in high-fat-diet-fed mice. J Nutr Biochem, 59:76-83.

[151] Bialesova L, Kulyte A, Petrus P, Sinha I, Laureenckiene J, Zhao C, et al. (2017). Epigenetic Regulation of PLIN 1 in Obese Women and its Relation to Lipolysis. Sci Rep, 7:10152.

[152] Dick KJ, Nelson CP, Tsaprouni L, Sandling JK, Assi D, Wahl S, et al. (2014). DNA methylation and body-mass index: a genome-wide analysis. Lancet, 383:1990-1998.

[153] Ling C, Ronn T (2019). Epigenetics in Human Obesity and Type 2 Diabetes. Cell Metab, 29:1028-1044.

[154] Long KR, Ma JD, Chen L, Wang PJ, He DF, Li MZ, et al. (2015). Promoter and first exon methylation regulate porcine FASN gene expression. Genet Mol Res, 14:8443-8450.

[155] Schleinitz D, Kloting N, Korner A, Berndt J, Reichenbacher M, Tonjes A, et al. (2010). Effect of genetic variation in the human fatty acid synthase gene (FASN) on obesity and fat depot-specific mRNA expression. Obesity (Silver Spring), 18:1218-1225.

[156] Jung SE, Lim SM, Hong SR, Lee EH, Shin KJ, Lee HY (2018). DNA methylation of the ELOVL2, FHL2, KLF14, C1orf132/MIR29B2C, and TRIM59 genes for age prediction from blood, saliva, and buccal swab samples. Forensic Sci Int Genet, 38:1-8.

[157] Horvath S (2013). DNA methylation age of human tissues and cell types. Genome Biol, 14:R115.

[158] Duteil D, Tosic M, Willmann D, Georgiadi A, Kanouni T, Schule R (2017). Lsd1 prevents age-programmed loss of beige adipocytes. Proc Natl Acad Sci U S A, 114:5265-5270.

[159] Khan C, Pathe N, Fazal S, Lister J, Rossetti JM (2012). Azacitidine in the management of patients with myelodysplastic syndromes. Ther Adv Hematol, 3:355-373.

[160] Lubbert M, Succi S, Hagemeijer A, Ruter B, Platzbecker U, Giagounidis A, et al. (2016). Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Ann Hematol, 95:191-199.

[161] Borges S, Doppler HR, Storz P (2014). A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells. Breast Cancer Res Treat, 144:79-91.

[162] Xue ZT, Sjogren HO, Salford LG, Widdegren B (2012). An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-gamma: potential therapeutic use in autoimmune diseases. Mol Immunol, 51:101-111.

[163] Khan H, Vale C, Bhagat T, Verma A (2013). Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol, 50:16-37.

[164] Medina-Franco JL, Caulfield T (2011). Advances in the computational development of DNA methyltransferase inhibitors. Drug Discov Today, 16:418-425.

[165] Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD (2019). Epigenetic therapy in immune-oncology. Nat Rev Cancer, 19:151-161.

[166] Wang Y, Zhang L, Wu GR, Zhou Q, Yue H, Rao LZ, et al. (2021). MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program. Sci Adv, 7.

[167] Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A (2001). Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev, 15:710-723.

Berger J, Sansom O, Clarke A, Bird A (2007). MBD2
is required for correct spatial gene expression in the gut. Mol Cell Biol, 27:4049-4057.

[169] Berger J, Bird A (2005). Role of MBD2 in gene regulation and tumorigenesis. Biochem Soc Trans, 33:1537-1540.

[170] Frasca D, Blomberg BB (2020). Adipose tissue, immune aging, and cellular senescence. Semin Immunopathol, 42:573-587.

[171] Fujii N, Uta S, Kobayashi M, Sato T, Okita N, Higami Y (2019). Impact of aging and caloric restriction on fibroblast growth factor 21 signaling in rat white adipose tissue. Exp Gerontol, 118:55-64.

[172] Pan X, Yan W, Qiu B, Liao Y, Liao Y, Wu S, et al. (2020). Aberrant DNA methylation of Cyclin-D-CDK4-p21 is associated with chronic fluoride poisoning. Chem Biol Interact, 315:108875.

[173] Qimuge N, He Z, Qin J, Sun Y, Wang X, Yu T, et al. (2019). Overexpression of DNMT3A promotes proliferation and inhibits differentiation of porcine intramuscular preadipocytes by methylating p21 and PPARg promoters. Gene, 696:54-62.